InMed Pharmaceuticals, Inc. (INM)

NASDAQ: INM · IEX Real-Time Price · USD
0.490
0.000 (0.02%)
At close: Jun 24, 2022 4:00 PM
0.510
+0.020 (4.082%)
After-hours: Jun 24, 2022 4:16 PM EDT
0.02%
Market Cap 10.03M
Revenue (ttm) 574,677
Net Income (ttm) -13.99M
Shares Out 20.47M
EPS (ttm) -1.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 103,917
Open 0.472
Previous Close 0.490
Day's Range 0.470 - 0.510
52-Week Range 0.417 - 3.470
Beta 1.41
Analysts Buy
Price Target 3.47 (+608.2%)
Earnings Date May 12, 2022

About INM

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology... [Read more...]

Industry Biotechnology
CEO Eric Adams
Employees 12
Stock Exchange NASDAQ
Ticker Symbol INM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for INM stock is "Buy." The 12-month stock price forecast is 3.47, which is an increase of 608.16% from the latest price.

Price Target
$3.47
(608.16% upside)
Analyst Consensus: Buy
Stock Forecasts

News

InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and oth...

VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercializa...

InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector

VANCOUVER, British Columbia, June 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercializa...

InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The...

VANCOUVER, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercializa...

InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates

InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -8.70% and 27.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update

VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, ...

InMed to Supply Rare Cannabinoids to Radicle Science's “Radicle Energy Study” to Assess the Health Effects of THCV

VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, ...

InMed Pharmaceuticals (INM): Notable Launches of High-Value Rare Cannabinoids

LONDON, UK / ACCESSWIRE / May 3, 2022 / InMed Pharmaceuticals (INM) continues its transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness ma...

InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Canna...

VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development...

InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development...

InMed to Participate in Upcoming Investor Conferences in April and May 2022

VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercializ...

InMed Announces Management Changes

VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercializ...

InMed to Present at the 34th Annual Roth Conference

Vancouver, BC, March 08, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commer...

InMed Pharmaceuticals (INM): Generating Commercial Sales of CBC and CBT

LONDON, UK / ACCESSWIRE / February 16, 2022 / InMed Pharmaceuticals' (INM's) Q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wel...

InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and ...

VANCOUVER, British Columbia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercializa...

InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss, Tops Revenue Estimates

InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -29.17% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

VANCOUVER, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of ra...

InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022

VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercializa...

InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercializa...

InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook

VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of ra...

Registration Now Open For Tribe Public's Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featu...

Meet with InMed's CEO Eric A. Adams, Shane Johnson, SVP and General Manager of BayMedica and Chris Meiering, VP of Commercial Operations Meet with InMed's CEO Eric A. Adams, Shane Johnson, SVP and Gener...

InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for G...

VANCOUVER, British Columbia, Dec. 20, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of ra...

InMed Announces Results of 2021 Annual General Meeting

VANCOUVER, British Columbia, Dec. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of ra...

Best Penny Stocks To Buy Now? 5 To Watch Before Next Week

Are these on your list of penny stocks right now? The post Best Penny Stocks To Buy Now?

Other symbols: AMPYCPGTIVCVLON

InMed Pharmaceuticals to Participate in Cowen's 4th Annual Cannabis Conference

VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of ra...

Welcome to the Party $INM! Competition or Compliment to $SNDL?

South Dakota lawmakers recommend bill to legalize marijuana. New York bans advertising for cannabis and psychedelics in subways.

Other symbols: SNDL